

Patent Updates

Suven Life Sciences secures Product Patents in Aripo, India, New Zealand, Singapore and Sri Lanka

HYDERABAD, INDIA (Mar 22, 2021) – Suven Life Sciences Ltd secures two (2) product patents from Aripo (AP 5299 and AP 5405) one (1) product patent from India (354994), One (1) product patent from New Zealand (750150), one (1) product patent from Singapore (11201902505X) and one (1) product patent from Sri Lanka (20439) corresponding to the new Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2035, 2036 and 2037 respectively.

The granted claims of the patents include the class of selective 5HT₃, 5HT₄, 5HT₆, H₃ and M₁PAM compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.

Disclaimer and Risk Statement:

Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time

Suven Life Sciences Limited